Pacira BioSciences (PCRX) said Monday that two-year results from a Phase 1 study showed its gene therapy candidate PCRX-201 provided sustained improvements in pain, stiffness, and function in patients with knee osteoarthritis.
Patients who received corticosteroid pretreatment experienced greater reductions in pain and stiffness, the company said.
PCRX-201, which boosts production of an anti-inflammatory protein, was generally well tolerated, with mild to moderate joint swelling as the most common side effect.
Pacira is currently enrolling patients in a phase 2 study of PCRX-201 for knee osteoarthritis.
Shares of Pacira were up 2.7% in recent trading.
Price: 26.41, Change: +0.69, Percent Change: +2.68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.